Faculty Perspectives June 2013 Vol 4 No 4 TON

Faculty Perspectives

Hematologic Cancers

Axicabtagene Ciloleucel Induces Durable Responses in Advanced Follicular Lymphoma and Marginal-Zone Lymphoma

By William King

CAR T-Cell Therapy Shows Highly Durable Remissions in CLL and B-Cell Lymphoma

By Charlie Dawson

November 4, 2019 — Oncology News & Updates

View More Articles

In the News

CMS Expands Access to Telehealth Benefits During COVID-19 Outbreak

FDA Grants Priority Review to New Drug Application for the RET Kinase Inhibitor Selpercatinib

Tazverik Receives FDA Approval as First Treatment Specifically for Metastatic or Locally Advanced Epithelioid Sarcoma

View More Articles

Lung Cancer

Sotorasib Conveys Long-Term Benefits in Patients With KRAS G12C–Mutated Non–Small Cell Lung Cancer

NGS Testing More Cost-Effective Than SGT in Oncology

Phase 3 Study of Sotorasib in NSCLC Demonstrated Shorter PFS Than Phase 1/2 Trials

View More Articles

Supportive Care

Restrictive Diet May Not Be Necessary for Patients Undergoing HSCT

By Patricia Stewart

Psychosocial Issues in Patients with Cancer: It’s Time for Real-World Interventions

By Corbin Davis

Medical Cannabis in Patients with Advanced Cancer: Challenges Remain

By Corbin Davis

View More Articles

FDA Updates

FDA News: October 11, 2023, to November 16, 2023

FDA News: July 20, 2023, to August 14, 2023

FDA News: May 19, 2023, to June 20, 2023

View More Articles

Breast Cancer

Adjuvant T-DM1 Improves Survival vs Trastuzumab in Early High-Risk HER2-Positive Breast Cancer

By Phoebe Starr

Supervised Exercise Program Enhances Quality of Life and Fitness in Patients With Metastatic Breast Cancer

By Wayne Kuznar

Ribociclib Plus Endocrine Therapy Improves Invasive Disease-Free Survival in Patients With HR-Positive, HER2-Negative, Early Breast Cancer

By Patricia Stewart

View More Articles

Novel Approaches in the Treatment of Hematologic Malignancies Utilizing Bendamustine

Hematologic Cancers

Faculty Perspectives June 2013 Vol 4 No 4 TON

This article discusses ongoing clinical investigations of the agent in a wide range of therapeutic areas. Read More ›

Advances in Bendamustine Clinical Trials TON

By Colleen Ross, RN, MSN, MHA, OCN

Hematologic Cancers

Faculty Perspectives June 2013 Vol 4 No 4 TON

Bendamustine is currently approved for the treatment of chronic lymphocytic leukemia (CLL), and many ongoing studies are investigating its efficacy in drug combinations. Read More ›

The Developing Treatment Role of Bendamustine TON

By Susanne Liewer, PharmD, BCOP

Hematologic Cancers

Faculty Perspectives June 2013 Vol 4 No 4 TON

Bendamustine has demonstrated activity as monotherapy and in combination for patients with lymphoid and hematologic as well as solid tumors. Read More ›

Bendamustine: Progress in Clinical Investigations TON

By Julie M. Vose, MD, MBA

Hematologic Cancers

Faculty Perspectives June 2013 Vol 4 No 4 TON

At the 54th Annual Meeting of the American Society of Hematology, a number of abstracts were presented demonstrating the efficacy and toxicities of bendamustine either alone or in combination with other agents for the treatment of several lymphoid malignancies such as chronic lymphocytic leukemia (CLL) and indolent as well as aggressive non-Hodgkin lymphoma (NHL). Read More ›

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

TON Print Edition

TON Weekly e‑Newsletter

I have reviewed and consent to the terms of TON's Privacy Policy, and TON has my permission to retain my information in its database, and to forward pertinent communications to me.